Targovax, a Norway-based clinical stage immuno-oncology company, has named Catherine Wheeler as its new director, it was reported yesterday.

Most recently, Wheeler served Acetylon Pharmaceutical as chief medical officer and prior to that she held progressively senior clinical and business development roles at Roche, AstraZeneca and Parexel.

Patrick Vink, chairman of the board at Targovax, said, 'We are delighted to welcome Catherine, she brings extensive international oncology expertise and insights that will further strengthen the board. She has had a long and distinguished career and has significant experience of bringing innovative oncology treatments to market that will be invaluable as we continue to progress the clinical development of our novel and complementary portfolio of cancer immunotherapies.'